David Ricks, Eli Lilly CEO (Carolyn Kaster/AP Images)
Lilly inks $2.4B cash deal to buy DICE and its immunology pipeline
Eli Lilly is joining the “blistering” pace of M&A this year as it bets $2.4 billion in cash on DICE Therapeutics, a publicly traded biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
